Cyclooxygenase-2 expression in medullary thyroid carcinoma

Head and Neck

Volumn 29, Issue 6, 2007, Pages 559-563

  Popovtzer, Aron ^a,b   Morgenstein, Sara ^a,b   Roizman, Pepi ^a   Gutman, Dan ^a,b   Bahar, Gidi ^a,b   Stern, Yoram ^a,b   Feinmesser, Rafael ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Colloid goiter; COX 2; Medullary thyroid carcinoma

Indexed keywords

CYCLOOXYGENASE 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOGRAM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYROID MEDULLARY CARCINOMA;

ADENOMA; ADOLESCENT; ADULT; AGED; CARCINOMA, MEDULLARY; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; STAINING AND LABELING; THYROID NEOPLASMS; THYROID NODULE;

EID: 34548284353     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20542     Document Type: Article

References (36)

1. Hyer SL, Vini L, A'Hern R, Harmer C. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 2000;26:686-690.
2. Vitale G, Caraglia M, Ciccarelli A, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001;91:1797-1808.
3. Kakudo K, Carney JA, Sizemore GW. Medullary carcinoma of thyroid. Biologic behavior of the sporadic and familial neoplasm. Cancer 1985;55:2818-2822.
4. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148.
5. Girelli ME, Nacamulli D, Pelizzo MR, et al. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986. Thyroid 1998;8: 517-523.
6. Rossi RL, Cady B, Meissner WA, Wool MS, Sedgwick CE, Werber J. Nonfamilial medullary thyroid carcinoma. Am J Surg 1980;139:554-560.
7. Schroder S, Bocker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 1988;61:806-816.
8. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 1997;103:60-69.
9. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S. Panzarella medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-310.
10. Gillenwater AM, Weber RS. Thyroid carcinoma. Cancer Treat Res 1997;90:149-169.
11. Saad MF, Guido JJ, Samaan NA. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1983;57:124-128.
12. Scherubl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 1990; 116:21-23.
13. Porter AT, Ostrowski MJ. Medullary carcinoma of the thyroid treated by low-dose Adriamycin. Br J Clin Pract 1990;44:517-518.
14. Stein R, Chen S, Reed L, Richel H, Goldenberg DM. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer 2002;94:51-61.
15. Lupoli GA, Fonderico F, Fittipaldi MR, et al. The role of somatostatin analogs in the management of medullary thyroid carcinoma. J Endocrinol Invest 2003;26 (Suppl):72-74.
16. Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lanreotide in combination with interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000;85:983-988.
17. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-994.
18. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A 1996;93:4816-4820.
19. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-4429.
20. Gridelli C, Maione P, Airoma G, Rossi A. Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr Med Chem 2002;9:1851-1858.
21. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-990.
22. Honjo S, Kase S, Osaki M, Ardyanto TD, Kaibara N, Ito H. COX-2 correlates with F-box protein, Skp2 expression and prognosis in human gastric carcinoma. Int J Oncol 2005;26:353-360.
23. Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999;46:407-412.
24. Nijsten T, Colpaert CG, Vermeulen PB, Harris AL, Van Marck E, Lambert J. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 2004;151:837-845.
25. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
26. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-1594.
27. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
28. Brunda MJ, Herberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980;124:2682-2687.
29. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3:295-315.
30. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-4760.
31. Williams ED, Karim SM, Sandler M. Prostaglandin secretion by medullary carcinoma of the thyroid. A possible cause of the associated diarrhoea. Lancet 1968;1:22-23.
32. Ito Y, Yoshida H, Nakano K, et al. Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 2003;42:492-497.
33. Cornetta AJ, Russell JP, Cunnane M, Keane WM, Rothstein JL. Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 2002;112:238-242.
34. Smith TJ, Jennings TA, Sciaky D, Cao HJ. Prostaglandin-endoperoxide H synthase-2 expression in human thyroid epithelium. Evidence for constitutive expression in vivo and in cultured KAT-50 cells. J Biol Chem 1999;274:15622-15632.
35. Quidville V, Segond N, Pidoux E, Cohen R, Jullienne A, Lausson S. Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology 2004;145:2561-2571.
36. Peek RM Jr. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemother Pharmacol 2004;54 (Suppl 1):S50-S56.